P&G dandruff study
This article was originally published in The Rose Sheet
Executive Summary
Zinc contained in pyrithione zinc anti-dandruff formulas is not inert, but rather improves the efficacy of the complex when adequately partnered with pyrithione, leading to improved PTZ formulation technology, according to Procter & Gamble. The company says it previously believed pyrithione alone was active in PTZ. Conducted by P&G researchers including James Schwartz, PhD, findings build on a prior P&G study that identified Malassezia globosa as the exact fungal species that causes dandruff. The new study, which further explored the mechanism by which PTZ fights Malassezia, found that PTZ's "bioavailability and antifungal activity is maximized by preventing PT from dissociating from the zinc ion during treatment," the firm claims. The findings have not been published, and P&G would not comment on plans to do so in the near term...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.